<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01835730</url>
  </required_header>
  <id_info>
    <org_study_id>PE0139-PT-CL-0001</org_study_id>
    <nct_id>NCT01835730</nct_id>
  </id_info>
  <brief_title>Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PhaseBio Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PhaseBio Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first-in-human randomized, double-blind (Investigator and subject), placebo
      controlled single ascending dose study that will enroll approximately 40 (6 active/2 placebo
      per dose group) adult male and female subjects with Type 2 Diabetes Mellitus (T2DM).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Vital Signs from baseline (Day 0 Pre-dose)</measure>
    <time_frame>Vital signs Day 0, 1, 2, 3, 4, 5, 6, 7, 14 and 28</time_frame>
    <description>Safety will be evaluated by analyses of the change from baseline in vital signs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ECGs from baseline (Day -1)</measure>
    <time_frame>ECG Days 2 and 28</time_frame>
    <description>Safety will be evaluated by analyses of the change from baseline in 12-lead ECG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Safety Labs from baseline (Pre-dose)</measure>
    <time_frame>Safety Labs Days 0, 7 and 28</time_frame>
    <description>Safety will be evaluated by analyses of the safety laboratory parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of immunogenicity</measure>
    <time_frame>Immunogenicity Days 0, 7, 14 and 28</time_frame>
    <description>Safety will be evaluated by the incidence and severity of immunogenicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events including hypoglycemia</measure>
    <time_frame>As reported between Days -10 to 28</time_frame>
    <description>Safety will be evaluated by the incidence and severity of adverse events including hypoglycemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile</measure>
    <time_frame>Day 0, 1, 2, 3, 4, 5, 6, and 7</time_frame>
    <description>Pharmacokinetic parameters include: Area under the concentration curve from time 0 to infinity (AUC(0-inf)), Area under the concentration curve to the final sample with a concentration greater than or equal to Limit of Quantitation (LOQ) (AUC(0-t)), Time to maximum concentration (Tmax), Maximum serum concentration (Cmax), Elimination rate constant (Lambda-z), Elimination half-life (t1/2), Clearance uncorrected for bioavailability (CL/F), Distribution uncorrected for bioavailability (Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Response</measure>
    <time_frame>FPG Day -10, -4, 0, 1, 2, 3, 4, 5, 6, 7, and 28; 4-pt Glucose and CGM - Day -10 to -7, -6, -5, and -4 to 7</time_frame>
    <description>To assess the pharmacodynamic response (time action profile) of various single doses of PE0139. Assessments include Fasting plasma glucose (FPG), 4-point serial glucose monitoring and glucose assessed by continuous glucose monitoring (CGM).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Type 2 Diabetes Mellitus (T2DM)</condition>
  <arm_group>
    <arm_group_label>PE0139 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous injection of PE0139, 40 mg/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single subcutaneous injection of 0.9% Sodium Chloride (NaCl) (Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PE0139 Injection</intervention_name>
    <arm_group_label>PE0139 Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to sign a written informed consent and follow all study-related
             procedures;

          -  Male and female subjects at least 18 years of age;

          -  Male subjects and female subjects of childbearing potential must practice effective
             contraception during the study and be willing and able to continue contraception for
             30 days after their dose of study drug;

          -  Body mass index ≤45 kg/m2;

          -  Diagnosed with T2DM and who is currently taking a stable daily dose of a basal insulin
             (Lantus) plus at least one oral antihyperglycemic agent at a stable dose for 3 months
             prior to screening.

        Exclusion Criteria:

          -  Currently taking or have taken within 3 months prior to screening an approved or
             investigational GLP-1 analogue/agonist (e.g., Victoza®) or pramlintide;

          -  Currently taking or have routinely taken, within 3 months prior to screening , a
             short-acting insulin;

          -  Currently taking or have taken, within 3 months prior to screening, a long acting
             insulin other than Lantus®;

          -  Known allergy to, or serious adverse effect caused by an approved, or investigational
             insulin product or any of its components;

          -  Currently taking any of the following medications: thiazide or furosemide diuretics,
             beta-blockers, estrogens or other hormonal replacement therapy, or other chronic
             medications with known adverse effects on glucose tolerance levels unless the subject
             has been on stable doses of such agents for at least 2 months prior to screening and
             have no planned changes during the study period;

          -  History of recurrent severe hypoglycemia (more than 2 episodes within the last 6
             months prior to randomization or hypoglycemic unawareness;

          -  Malignant disease defined as 1) any history of malignant melanoma or breast cancer
             and/or 2) history of other types of cancer within the last 5 years prior to screening;

          -  Unstable cardiovascular disease defined as one or more of the following: History of
             stroke, transient ischemic attack, or myocardial infarction within 6 months prior to
             screening; History of or currently have New York Heart Association Class III-IV heart
             failure prior to screening; Uncontrolled/sustained hypertension; History or evidence
             of long QT syndrome or mean triplicate 12-lead electrocardiogram demonstrating QT
             interval;

          -  Clinically significant renal and/or hepatic dysfunction;

          -  Absolute requirement for corticosteroids or have received systemic steroids within 3
             months prior to Randomization (V5, Day -1). Note: Use of inhaled or topical
             corticosteroids will be permitted;

          -  Pregnant or lactating female subjects;

          -  Known history of or active alcohol abuse or use of illicit drugs within 1 year prior
             to screening;

          -  Positive screening for human immunodeficiency virus antibodies, hepatitis B surface
             antigen, or hepatitis C virus antibodies at V1;

          -  Participating in any other study and have received any other investigational
             medication or device within 30 days prior to Visit 1.

          -  Other medical or psychiatric condition which, in the opinion of the Investigator,
             would place the subject at increased risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Brazg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rainier Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Springs Research Institute</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2013</study_first_submitted>
  <study_first_submitted_qc>April 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2013</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

